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Abstract
Background: Isoprenylcysteine carboxyl methyltransferase (Icmt) is the third of three enzymes
that posttranslationally modify proteins that contain C-terminal CaaX motifs. The processing of
CaaX proteins through this so-called prenylation pathway via a route initiated by addition of an
isoprenoid lipid is required for both membrane targeting and function of the proteins. The
involvement of many CaaX proteins such as Ras GTPases in oncogenesis and other aberrant
proliferative disorders has led to the targeting of the enzymes involved in their processing for
therapeutic development, necessitating a detailed understanding of the mechanisms of the enzymes.
Results: In this study, we have investigated the kinetic mechanism of recombinant human Icmt. In
the reaction catalyzed by Icmt, S-adenosyl-L-methionine (AdoMet) provides the methyl group that
is transferred to the second substrate, the C-terminal isoprenylated cysteine residue of a CaaX
protein, thereby generating a C-terminal prenylcysteine methyl ester on the protein. To facilitate
the kinetic analysis of Icmt, we synthesized a new small molecule substrate of the enzyme, biotin-
S-farnesyl-L-cysteine (BFC). Initial kinetic analysis of Icmt suggested a sequential mechanism for the
enzyme that was further analyzed using a dead end competitive inhibitor, S-farnesylthioacetic acid
(FTA). Inhibition by FTA was competitive with respect to BFC and uncompetitive with respect to
AdoMet, indicating an ordered mechanism with SAM binding first. To investigate the order of
product dissociation, product inhibition studies were undertaken with S-adenosyl-L-homocysteine
(AdoHcy) and the N-acetyl-S-farnesyl-L-cysteine methylester (AFCME). This analysis indicated that
AdoHcy is a competitive inhibitor with respect to AdoMet, while AFCME shows a noncompetitive
inhibition with respect to BFC and a mixed-type inhibition with respect to AdoMet. These studies
established that AdoHcy is the final product released, and that BFC and AFCME bind to different
forms of the enzyme.
Conclusions: These studies establish that catalysis by human Icmt proceeds through an ordered
sequential mechanism and provide a kinetic framework for analysis of specific inhibitors of this key
enzyme.
Background
Posttranslational modification of eukaryotic proteins
with lipids is a prevalent mechanism for controlling the
subcellular localization and activity of these proteins [1].
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Most proteins terminating in a CaaX sequence (C,
cysteine; "a", generally an aliphatic residue; X, the car-
boxy-terminal residue) are subject to modification by iso-
prenoid lipids via their ability to serve as substrates for
protein farnesyltransferase or protein geranylgeranyltrans-
ferase type I [2]. Following covalent attachment of the far-
nesyl or geranylgeranyl isoprenoid to the Cys thiol of the
CaaX sequence, the majority of these proteins are further
processed by removal of the carboxyl-terminal aaX resi-
dues by an endoprotease termed Rce1 and methylation of
the newly-exposed carboxyl group of the isoprenylated
cysteine residue by an enzyme termed isoprenylcysteine
carboxylmethyltransferase (Icmt) [3,4].
While isoprenoid modification of CaaX proteins is the
principal determinant of their membrane targeting, the
subsequent steps of proteolysis and methylation are
clearly important. Studies performed using small mole-
cule prenylcysteines such as N-acetyl-S-farnesyl-L-cysteine
(AFC) and N-acetyl-S-geranylgeranyl-L-cysteine (AGGC)
[5] showed that carboxyl methylation is a critical determi-
nant of the hydrophobicity of the farnesylated moiety,
whereas in the case of geranylgeranylated counterpart the
effect is much less. Similar results were obtained in studies
with short prenylated peptides [6]. Ras proteins, which are
primarily farnesylated, are largely mislocalized in cells in
which the Icmt gene has been disrupted and in cells in
which the methylation pathway has been perturbed [7,8],
suggesting that this processing step is critical for traffick-
ing and/or stable membrane association. In more biolog-
ical settings, disruption of either the Rce1 or Icmt genes in
mice results in embryonic lethality [9,10], and a very
recent study has shown that genetic disruption of Icmt in
cells dramatically attenuates their ability to be trans-
formed by the K-Ras oncogene [11]. Altogether, a picture
has emerged in which C-terminal methylation of pre-
nylated proteins is thought to contribute substantially to
their affinity for cell membranes [12-15], to influence
rates of protein turnover [11,16], and to facilitate func-
tional interactions with other proteins [17-19].
Although Icmt is a protein methyltransferase, the enzyme
can efficiently modify simple prenylcysteines [6,20-22], a
property that has the potential to greatly facilitate kinetic
analysis of the enzyme. The only kinetic study of an iso-
prenylcysteine methyltransferase activity to date was per-
formed prior to the molecular identification of Icmt and
involved kinetic analysis of a methyltransferase activity in
retinal rod outer segment membranes that was capable of
modifying the small molecule substrate N-acetyl-L-far-
nesylcysteine (AFC) [20]. However, the cloning of mam-
malian Icmt [23], and the development of an expression
system to produce recombinant protein [8], now allows
an unambiguous analysis of the properties of this impor-
tant enzyme. Here we report studies of the kinetic mecha-
nism of recombinant human Icmt produced in Sf9 cells.
This analysis was also facilitated by the synthesis of a new
small molecule Icmt substrate, biotin-S-farnesyl-L-
cysteine (BFC), that allowed development of a facile assay
for enzyme activity. Through standard Michaelis-Menten
analysis as well as product competition and dead-end
inhibitor studies, we demonstrate that catalysis by Icmt
proceeds through an ordered sequential mechanism in
which the substrate AdoMet binds first and its product
AdoHCy is released last.
Results
Characterization of the small molecule Icmt substrate, 
BFC
To overcome the inherent problems associated with use of
S-prenylated peptides and proteins as Icmt substrates
(expense in production, unwieldy separation techniques,
etc), we synthesized a small molecule substrate for the
enzyme that contains an appended biotin moiety (Fig.
1A) to facilitate the separation required for product anal-
ysis. The coupling of biotin moiety to the free amino
group of the S-farnesylcysteine, FC, was readily achieved
through the use of commercial biotin N-hydroxysuccin-
imide ester and the product BFC could be readily purified
by precipitation or by reverse-phase chromatography (see
Methods). BFC was characterized in terms of its ability to
serve as a substrate for recombinant human Icmt using a
standard in vitro methylation assay (Fig. 1B). The apparent
Km of BFC was 2.1 ± 0.4 µM, which is essentially identical
to the Km of 2.1 µM determined for farnesylated, Rce1-
proteolyzed K-Ras (data not shown). Hence, BFC is a com-
parable to K-Ras as an Icmt substrate and has the added
advantages of being a stable small molecule that can be
readily captured on avidin resins.
Distinguishing ping-pong vs. sequential kinetic mechanisms 
for human Icmt
Detailed knowledge of the kinetic mechanism of an
enzyme is very important in providing the foundation for
analysis of structure-function studies and in inhibitor
design studies. For a two substrate enzyme reaction such
as that catalyzed by Icmt, there are three basic mecha-
nisms: i) random sequential, ii) ordered sequential, and
iii) ping-pong [28,29]. Initial velocity studies can be used
to distinguish between a ping-pong mechanism, in which
a product is released between the addition of the two sub-
strates, and the sequential mechanisms, in which both
substrates must bind before any product is released.
Hence, in the first series of studies, the initial velocity of
the Icmt reaction at different substrates concentrations
was determined. In a ping-pong mechanism for an
enzyme with substrates A and B, the plots of 1/v versus 1/
[A] at different fixed [B], and vice versa, should yield par-
allel lines [28]. In a sequential mechanism, either ordered
or random, the family of reciprocal plots should intersectBMC Biochemistry 2004, 5:19 http://www.biomedcentral.com/1471-2091/5/19
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A new small-molecule substrate of Icmt Figure 1
A new small-molecule substrate of Icmt A. Structure of biotin-S-farnesyl-L-cysteine (BFC) B. Utilization of BFC as a sub-
strate by recombinant human Icmt. Shown are Michaelis-Menten and Lineweaver-Burk plot (inset) of the formation of BFC-
[3H]methylester as a function of BFC concentration. The data shown are the mean of duplicate determinations from a single 
experiment and are representative of two additional experiments.
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Distinguishing ping-pong vs. sequential kinetic mechanisms for human Icmt Figure 2
Distinguishing ping-pong vs. sequential kinetic mechanisms for human Icmt. A. Lineweaver-Burk plot for the meth-
ylation of BFC carried out in the presence of (◆ ) 2 µM, () 4 µM and (▲ ) 8 µM of BFC and varied [AdoMet]. B. Lineweaver-
Burk plot for the methylation of BFC carried out in the presence of () 5 µM, (■ ) 10 µM, (❍ ) 20 µM of AdoMet and varied 
[BFC]. For both experiments, the incubation time was 20 min and 0.5 µg of Sf9 membranes containing recombinant human 
Icmt protein were used for each condition. Data shown are the mean of duplicate determinations from a single experiment, 
and are representative to two such experiments.
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above the X axis (if the binding of A increase the interac-
tion with B), below the X-axis (if the binding of A
decreases the interaction with B), or on the X-axis (if the
binding of A has no effect on the interaction of B) [28].
The data obtained in the experiments where AdoMet con-
centration was varied at a series of fixed BFC concentra-
tions is shown in Fig 2A, and Fig. 2B shows the data
obtained when BFC concentration is varied at fixed
AdoMet concentrations. These results show that, in each
case, the families of reciprocal plots are not parallel and
intersect above the X-axis, ruling out the possibility of a
ping-pong mechanism. Moreover, the data for the experi-
ments in which BFC concentration was varied at fixed
AdoMet concentrations show an intersection of the recip-
rocal plots on Y-axis (Fig. 2B), indicating that the reaction
behaves as rapid-equilibrium bireactant system [28].
Distinguishing ordered sequential vs. random sequential 
mechanisms for human Icmt
While the initial velocity studies described above can dis-
tinguish between a ping-pong mechanism and a sequen-
tial mechanism, they cannot be used to distinguish an
ordered from a random mechanism. These two types of
sequential mechanisms can be distinguished, however,
through the use of so-called "dead-end" substrates that
cannot go on to form products [30]. Hence, we employed
such a dead-end inhibitor of Icmt, farnesylthioacetic acid
(FTA) [31], in kinetic studies. To distinguish between the
two types of inhibition patterns this compound was
examined for its inhibitory properties with respect to both
the cognate (BFC) and noncognate (AdoMet) substrates
under conditions where the fixed substrate was present at
nonsaturating concentrations. The results obtained dem-
onstrate that the FTA is a competitive inhibitor with
respect to BFC, with a measured Ki of 1.2 ± 0.2 µM (Fig,
3A, see also Table I). In contrast, the experiments per-
formed with varying AdoMet concentrations show a fam-
ily of parallel lines (Fig. 3B), which is a characteristic
profile for an uncompetitive inhibition [28,29]. If FTA
was able to combine with the free enzyme (i.e. the condi-
tion where its cognate substrate BFC binds first), the plots
in Fig. 3B would have yielded lines that intersect at nega-
tive 1/v and 1/[AdoMet] values, i.e. FTA should have
shown a mixed-type inhibitor with respect to AdoMet
[20]. These results indicate that Icmt reaction occurs
through an ordered mechanism in which AdoMet binds
first to the enzyme followed by BFC binding to the
AdoMet-Icmt binary complex.
Distinguishing the order of product dissociation from 
human Icmt
Two products are formed in the reaction catalyzed by
Icmt, a methylated prenylcysteine (in vivo on proteins, but
in vitro also on small molecules or peptides) and AdoHcy.
To determine the order of the dissociation of these two
products, we performed product inhibition using the pre-
nylcysteine methylester, AFCME, and AdoHcy. Examina-
tion of the initial rates of product formation at fixed BFC
and varying AdoMet concentrations in presence of three
concentrations of AdoHcy (Fig. 4A), revealed that AdoHcy
is a competitive inhibitor with respect to AdoMet with an
apparent Ki of 3.5 ± 1.0 µM (Table I). This finding is con-
sistent with both AdoMet and AdoHcy binding to the
same form of Icmt, ie. the free enzyme, suggesting that
AdoMet binds first in an ordered mechanism and that
AdoHcy is the last product released. When the same exper-
iment was performed at varying BFC concentrations, a
very similar pattern was observed (Fig. 4B), revealing that
AdoHcy is also a competitive inhibitor with respect to BFC
with a Ki of 3.6 ± 1.0 µM. While a classic ordered sequen-
tial mechanism in which AdoHcy was released last would
result in this type of inhibition being non-competitive or
mixed-type, this type of behavior in which a single prod-
uct binds competitively with both substrates can also be
observed in ordered bireactant systems that proceed via a
rapid equilibrium process [28].
The product inhibition experiments were next repeated
with AFCME as the second class of product inhibitor. An
ordered sequential mechanism with initial departure of
the methylated prenylcysteine product requires that non-
competitive or mixed-type inhibition be observed with
respect to both of the substrates of the reaction [29]. The
data obtained with L-AFC did indeed demonstrate pre-
cisely this [20]. Noncompetitive inhibition by AFCME
was observed with respect to the BFC substrate (Fig. 5A)
with an apparent Ki of 1.9 ± 0.6 µM, and mixed-type inhi-
bition was observed with respect to AdoMet as a substrate
with an apparent Ki of 2.4 ± 0.7 µM, respectively (Fig. 5B).
These kinetic results are summarized in Table I. In addi-
tion, essentially identical results were observed with a sec-
ond prenylcysteine-type product analog N-acetyl-S-
farnesyl-L-cysteine methyl amide (AFCMA) (data not
shown). Altogether, the results this kinetic analysis are
completely consistent with the reaction catalyzed by Icmt
proceeding through an ordered sequential mechanism
with the AdoMet substrate binding first and the AdoHcy
product being released last.
Discussion
The studies in this report provide the first detailed kinetic
analysis of the molecular entity Icmt, the enzyme respon-
sible for the final step in the maturation of CaaX-type
protein in eukaryotic cells. To facility analysis of Icmt
activity, we synthesized a new substrate for Icmt, biotin-S-
farnesyl-L-cysteine (BFC), that has two properties that
improve its utility compared with the only other
described small molecule substrate for the enzyme, AFC.
First, BFC is utilized by the enzyme with a Km (2.1 µM)
essentially identical to that of an authentic substrate,BMC Biochemistry 2004, 5:19 http://www.biomedcentral.com/1471-2091/5/19
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Distinguishing ordered sequential vs. random sequential mechanisms for human Icmt Figure 3
Distinguishing ordered sequential vs. random sequential mechanisms for human Icmt. A. Lineweaver-Burk plot 
for the dead-end inhibition of BFC methylation by FTA at a fixed concentration of AdoMet. Assays were conducted in the 
presence of fixed [AdoMet] at 5 µM and either () 0 µM, (■ ) 5 µM or (❍ ) 10 µM of FTA at the indicated concentrations of 
BFC. B. Lineweaver-Burk plot for the dead-end inhibition of BFC methylation by FTA at a fixed concerntration of BFC. Assays 
were conducted in the presence of fixed [BFC] at 4 µM and either (◆ ) 0 µM, () 2.5 µM or (▲ ) 5 µM of FTA at the indicated 
concentrations of AdoMet. Assays were conducted as described in the legend to Fig. 2. Data shown are the mean of duplicate 
determinations from a single experiment, and are representative to two such experiments.
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farnesylated, Rce1-proteolyzed, K-Ras protein, whereas
the apparent Km for AFC is 10-fold higher at 20 µM
[20,31]. The second improvement in the BFC substrate is,
of course, the appended biotin moiety, which allows fac-
ile isolation of product from reaction mixtures using com-
mercially-available avidin resins. Furthermore, this
substrate is ideal for use in high-throughput screening for
inhibitors of the enzyme since it allows use of scintillation
proximity-type assays.
Our first series of kinetic studies was designed to distin-
guish between the two general kinetic mechanisms that
exist for multisubstrate enzymes. The first general mecha-
nism is termed sequential and describes reactions in
which all the substrates must bind to the enzyme before
the first product is released, whereas reactions in which
one or more products are released prior to all substrates
being added are termed ping-pong. To distinguish
between these reaction types, we performed classic steady
state kinetic analyses of Icmt. The results of this analysis
revealed that catalysis by Icmt exhibits all the properties of
rapid equilibrium bireactant system [28,29] and hence
proceeds via a sequential mechanism.
The second series of experiments we undertook was
designed to distinguish between a random sequential vs.
ordered sequential mechanism; this involved a determi-
nation of whether the enzyme could initially form a com-
plex with either substrate or whether must it bind them in
a defined order. To verify the assignment of a sequential
mechanism for Icmt and to distinguish between an
ordered versus a random sequential mechanism, studies
with a dead-end inhibitor of Icmt were performed. In a
random sequential mechanism, there is no defined order
of either substrate binding or product release, whereas in
an ordered sequential mechanism the binding of the first
substrate is required for the second and the products dis-
sociate in an obligatory order [28,29]. The studies with the
dead-end substrate FTA revealed that FTA is a competitive
inhibitor with respect to BFC, whereas in a random mech-
anism FTA would be expected to be a mixed-type inhibitor
with respect to AdoMet [28]. Furthermore the double-
reciprocal plots from the analysis of FTA as an inhibitor
with respect to AdoMet showed the parallel lines indica-
tive of an uncompetitive inhibition, signifying that FTA is
unable to bind to the free enzyme. Hence, AdoMet binds
first to enzyme and FTA interacts with the AdoMet-Icmt
complex since, if BFC combined first with enzyme, the
inhibition by FTA should have been competitive with
respect to BFC and a mixed-type, noncompetitive or com-
petitive inhibition with respect to AdoMet. Together,
these results indicate that the reaction catalyzed by Icmt is
proceeds through an ordered sequential mechanism in
which the AdoMet substrate binds first.
Following the assignment of a sequential mechanism for
Icmt, product inhibition experiments were employed to
investigate the order of product dissociation from the
enzyme. The finding that AdoHcy is a competitive inhibi-
tor with respect to AdoMet revealed that this compound
could interact with free enzyme; ie. it must be the final
product released. Also, the finding that the prenylcysteine
methylester AFCME exhibited mixed-type inhibition with
respect to AdoMet is the result expected if AdoHcy is the
last product released. Interestingly, when AdoHcy was
examined for its inhibition with respect to BFC a different
result was obtained from that of the previous kinetic study
of prenylcysteine methyltransferase activity in rod outer
segments [20]. With recombinant human Icmt, AdoHcy is
a competitive inhibitor with respect to BFC, indicating
that the Icmt-AdoHcy complex is inactive and cannot
bind to BFC, an observation that further reinforces the
conclusion of an ordered sequential mechanism for this
enzyme.
The inhibition constants for AFCME determined in our
experiments of 1.9 µM and 2.4 µM with respect to BFC
and AdoMet, respectively, are substantially different from
those in the previous study on the methyltransferase activ-
ity in rod outer segments of 41 µM and 73 µM respectively
[20]. We believe these results are more likely due to the
markedly enriched preparation used in our study rather
that to any fundamental difference in the enzyme activi-
ties; we used 1000-fold less membrane in our assays and
it is likely that the hydrophobic AFCME was substantially
"sopped up" by the membrane lipid in the previous study,
Table 1: Ki values and type of inhibition for the interaction of a dead-end inhibitor (FTA) and reaction products (AdoHCy, AFCME) 
with Icmt. The Km values obtained for the two substrates of the reaction, BFC and AdoMet, are also shown for comparaison.
Substrate\Inhibitor AdoHcy FTA AFCME
BFC Competitive Competitive Noncompetitive
Km = 2.1 ± 0.4 µM 3.59 ± 1.03 µM 1.17 ± 0.16 µM 1.91 ± 0.65 µM
AdoMet Competitive Uncompetitive Mixed-type
Km = 7.8 ± 1.2 µM 3.54 ± 1.12 µM 2.43 ± 0.70 µMBMC Biochemistry 2004, 5:19 http://www.biomedcentral.com/1471-2091/5/19
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Distinguishing the order of product dissociation from human Icmt: Inhibition studies with the AdoHcy product Figure 4
Distinguishing the order of product dissociation from human Icmt: Inhibition studies with the AdoHcy prod-
uct. A. Lineweaver-Burk plot for the product inhibition of BFC methylation by AdoHcy at a fixed concentration of BFC. Assays 
were conducted in the presence of fixed [BFC] at 4 µM and either (◆ ) 0 µM, () 5 µM or (▲ ) 10 µM of AdoHcy at the indi-
cated concentrations of AdoMet. Assays were conducted as described in the legend to Fig. 2. Data shown are the mean of 
duplicate determinations from a single experiment, and are representative to three such experiments. B. Lineweaver-Burk plot 
for the product inhibition of BFC methylation by AdoHcy at a fixed concentration of AdoMet. Assays were conducted in the 
presence of fixed [AdoMet] at 5 µM and either () 0 µM, (■ ) 2.5 µM, (❍ ) 5 µM, or (● ) 10 µM µM of AdoHcy at the indicated 
concentrations of BFC. Assays were conducted as described in the legend to Fig. 2. Data shown are the mean of duplicate 
determinations from a single experiment, and are representative to more than >4 such experiments.
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Distinguishing the order of product dissociation from human Icmt: Inhibition studies with the AFCME product Figure 5
Distinguishing the order of product dissociation from human Icmt: Inhibition studies with the AFCME product. 
A. Lineweaver-Burk plot for the product inhibition of BFC methylation by AFCME at a fixed concentration of BFC. Assays 
were conducted in the presence of fixed [BFC] at 4 µM and either (◆ ) 0 µM, () 5 µM or (▲ ) 10 µM of AFCME at the indi-
cated concentrations of AdoMet. Assays were conducted as described in the legend to Fig. 2. Data shown are the mean of 
duplicate determinations from a single experiment, and are representative to two such experiments. B. Lineweaver-Burk plot 
for the product inhibition of BFC methylation by AFCME at a fixed concentration of AdoMet. Assays were conducted in the 
presence of fixed [AdoMet] at 5 µM and either () 0 µM, (■ ) 5 µM or (❍ )10 µM of AFCME at the indicated concentrations of 
BFC. Assays were conducted as described in the legend to Fig. 2. Data shown are the mean of duplicate determinations from a 
single experiment, and are representative to more two such experiments.
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markedly reducing the level available to interact with the
enzyme. This phenomenon, which is related to that
known as surface dilution kinetics, comes into play when
both the concentration of the membrane lipid and of the
ligand employed contribute to the kinetic parameter
measured [32].
Conclusions
In summary, we have demonstrated that the kinetic mech-
anism of CaaX protein methylation by Icmt is an ordered
sequential mechanism in which the AdoMet substrate
associates first with the enzyme and the AdoHCy product
dissociates last. This work provides a kinetic framework
for the analysis of specific inhibitors of this enzyme that
will most assuredly be forthcoming given the recent bio-
logical validation of Icmt as a target for blocking onco-
genic transformation of cells [8,11,33].
Methods
Materials
Streptavidin-sepharose beads were purchased from Amer-
sham, trans, trans-farnesyl bromide, biotin N-hydroxysuc-
cinimide ester and S-(5'-adenosyl)-L-methionine p-
toluenesulfonate were purchased from Sigma-Aldrich, L-
cysteine was purchased from Novabiochem, [3H-methyl]-
S-adenosyl-L-methionine was purchased from Perkin
Elmer Life Sciences, farnesylthioacetic acid (FTA) was pur-
chased from Biomol, S-(5'-adenosyl)-L-homocysteine was
purchased from Fluka. The N-acetyl-S-farnesylcysteine
methyl ester (AFCME) and N-acetyl-S-farnesylcysteine
methyl amide (AFCMA) were synthesized as previously
described ([24-26]). Recombinant human Icmt was pre-
pared by infection of Sf9 cells with a recombinant baculo-
virus containing the entire open reading frame of the
human Icmt cDNA as described [8]. The membrane frac-
tion of the infected Sf9 cells, isolated as described for stud-
ies with the Rce1 protease [27], was used as the source of
Icmt for all studies described.
Syntheses of biotin-S-farnesyl L-cysteine (BFC)
S-Farnesyl L-cysteine (FC) was prepared by reaction of far-
nesyl bromide with L-cysteine in methanol/ammoniac
solvent as described [26]. The resultant FC product was
separated from L-cysteine by extraction with butanol/H2O
(1:1); the butanol phase was then evaporated under
reduce pressure and the FC product washed several times
with hexane to remove residual farnesyl bromide.
Two coupling procedures were used to attach the biotin
moiety to the amino group of FC; both involved the use
of biotin N-hydroxysuccinimide methylester (biotin-
NHS) as the biotinylation agent. In the first method, an
excess of biotin-NHS (75 µmol) to FC (7.5 µmol) was
used. The two compounds were dissolved in 2.3 ml of
DMSO and 200 µl of 1M Hepes, pH 12, was added.
Following a 2 h incubation at room temperature, the
DMSO was evaporated under reduced pressure and the
resulting residue extracted with a solution of butanol/
H2O (1:1). The butanol phase was dried and the residue
dissolved in 100 µl of methanol; this solution was then
diluted to 1 ml by addition of 0.1% trifluoroacetic acid
(TFA). The addition of the TFA resulted in the appearance
of a white precipitate of essentially pure BFC as judged by
chromatography and NMR analysis.
The second coupling method used an excess of FC (2.5
mmol) compared to biotin-NHS (0.73 mmol); these two
compounds were dissolved in 18 ml of DMSO. To this
solution was added 2 ml of 1M Hepes, pH 12, and the
coupling allowed to proceed for 2 h at room temperature.
As with the first method, the DMSO was evaporated under
reduced pressure, the resulting residue extracted with a
solution of butanol/H2O (1:1), and the butanol phase
dried and the residue dissolved in methanol. Because of
the excess of FC present with the BFC product, specific
precipitation of the BFC product was unsuccessful.
Instead, the BFC was purified by preparative HPLC on a
C18 column developed in CH3CN/H2O (2:3). On this
matrix, BFC was well-resolved from FC. The peak fractions
were collected and solvent evaporated under reduced
pressure; the resulting product was white solid that was
>95% pure as judged by analytical reverse-phase HPLC
[C18 matrix developed in CH3CN/H2O/TFA (90:10:0.1).
Proton NMR spectra of the products obtained by either
method were completely consistent with that expected for
authentic BFC.
Icmt assay
The assay developed for Icmt activity involved quantita-
tion of [3H]methyl incorporation into the small molecule
substrate BFC. For the standard assay, reactions were initi-
ated by addition of Sf9 membranes containing Icmt (0.5
µg protein) to an assay mixture containing BFC (4 µM)
and [3H]AdoMet (5 µM, 1.3 Ci/mmol) in100 mM Hepes,
pH 7.4 and 5 mM MgCl2 in a total volume of 45 µl. Reac-
tions were carried out for 20 min at 37°C, whereupon
they were terminated by addition of 5 µl of 10% Tween
20. Following termination, streptavidin beads (10 µl of
packed beads suspended in 500 µl of 20 mM NaH2PO4,
pH 7.4, contaning 150 mM NaCl) were added, and the
mixtures mixed by gentle agitation overnight at 4°C. The
beads were harvested by centrifugation in a tabletop
microcentrifuge at 10,000 rpm for 5 min and washed 3
times with 500 µl of 20 mM NaH2PO4, pH 7.4, containing
150 mM NaCl. The beads were then suspended in 100 µl
of the same buffer, transferred to scintillation vials, and
radioactivity determined. For the kinetic analyses, the
concentrations of substrates (AdoMet, BFC) or additional
ligands (eg. AdoHcy, AFCME, etc) were varied as detailed
in the legends to the appropriate figures.BMC Biochemistry 2004, 5:19 http://www.biomedcentral.com/1471-2091/5/19
Page 11 of 12
(page number not for citation purposes)
Abbreviations used
Icmt, Isoprenylcysteine carboxyl methyltransferase;
AdoMet, S-adenosyl-L-methionine; AdoHcy, S-adenosyl-
L-homocysteine; AFC, N-acetyl-L-farnesylcysteine; AGGC,
N-acetyl-S-geranylgeranyl-L-cysteine; TFA, trifluoroacetic
acid; BFC, biotin-S-farnesyl-L-cysteine; FTA, S-farnesylth-
ioacetic acid; AFCME, N-acetyl-S-farnesyl-L-cysteine
methylester; AFCMA, N-acetyl-S-farnesyl-L-cysteine
methyl amide
Authors' contributions
RAB carried out all of the studies reported. PJC conceived
of the study, and participated in its design and coordina-
tion and helped to draft the manuscript. Both authors
read and approved the final manuscript.
Acknowledgements
This work was supported by National Institutes of Health Grant GM46372 
to P.J.C. and fellowship to R.A.B. from l'Association pour la recherche con-
tre le cancer. We thank Dr. Rudolph for his helpful assistance in the kinetic 
experiments and for the use of his kinetic software.
References
1. Casey PJ: Protein lipidation in cell signaling.  Science 1995,
268(5208):221-225.
2. Casey PJ, Seabra MC: Protein prenyltransferases.  J Biol Chem
1996, 271(10):5289-5292.
3. Ashby MN: CaaX converting enzymes. Curr Opin Lipidol 1998,
9(2):99-102.
4. Young SG, Ambroziack P, Kim E, Clarke S: Post- isoprenylation
Protein Processing: CXXX (CaaX) Endoproteases and Iso-
prenylcysteine Carboxyl Methyltransferase. In In: The Enzymes
Volume 21. 3rd edition. Edited by: Tamanoi F, Sigman DG. San Diego:
Academic press; 2000:156-213. 
5. Parish CA, Rando RR: Isoprenylation/methylation of proteins
enhances membrane association by a hydrophobic
mechanism. Biochemistry 1996, 35(26):8473-8477.
6. Silvius JR, l'Heureux F: Fluorimetric evaluation of the affinities
of isoprenylated peptides for lipid bilayers. Biochemistry 1994,
33(10):3014-3022.
7. Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Young SG:
Targeted inactivation of the isoprenylcysteine carboxyl
methyltransferase gene causes mislocalization of K-Ras in
mammalian cells. J Biol Chem 2000, 275(23):17605-17610.
8. Winter-Vann AM, Kamen BA, Bergo MO, Young SG, Melnyk S, James
SJ, Casey PJ: Targeting Ras signaling through inhibition of car-
boxyl methylation: an unexpected property of
methotrexate. Proc Natl Acad Sci U S A 2003, 100(11):6529-6534.
9. Kim E, Ambroziak P, Otto JC, Taylor B, Ashby M, Shannon K, Casey
PJ, Young SG: Disruption of the mouse Rce1 gene results in
defective Ras processing and mislocalization of Ras within
cells. J Biol Chem 1999, 274(13):8383-8390.
10. Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Gomes AQ,
Seabra MC, Young SG: Isoprenylcysteine carboxyl methyltrans-
ferase deficiency in mice. J Biol Chem 2001, 276(8):5841-5845.
11. Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ,
Young SG: Inactivation of Icmt inhibits transformation by
oncogenic K-Ras and B-Raf. J Clin Invest 2004, 113(4):539-550.
12. Ghomashchi F, Zhang X, Liu L, Gelb MH: Binding of prenylated
and polybasic peptides to membranes: affinities and
intervesicle exchange. Biochemistry 1995, 34(37):11910-11918.
13. Hancock JF, Cadwallader K, Marshall CJ: Methylation and proteol-
ysis are essential for efficient membrane binding of pre-
nylated p21K-ras(B). Embo J 1991, 10(3):641-646.
14. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isopre-
noid addition to Ras protein is the critical modification for its
membrane association and transforming activity.  Proc Natl
Acad Sci U S A 1992, 89(14):6403-6407.
15. Parish CA, Smrcka AV, Rando RR: Functional significance of beta
gamma-subunit carboxymethylation for the activation of
phospholipase C and phosphoinositide 3-kinase. Biochemistry
1995, 34(23):7722-7727.
16. Backlund PS Jr: Post-translational processing of RhoA. Car-
boxyl methylation of the carboxyl-terminal prenylcysteine
increases the half-life of Rhoa.  J Biol Chem 1997,
272(52):33175-33180.
17. Higgins JB, Casey PJ: In vitro processing of recombinant G pro-
tein gamma subunits. Requirements for assembly of an
active beta gamma complex.  J Biol Chem 1994,
269(12):9067-9073.
18. Rosenberg SJ, Rane MJ, Dean WL, Corpier CL, Hoffman JL, McLeish
KR: Effect of gamma subunit carboxyl methylation on the
interaction of G protein alpha subunits with beta gamma
subunits of defined composition. Cell Signal 1998, 10(2):131-136.
19. Chen Z, Otto JC, Bergo MO, Young SG, Casey PJ: The C-terminal
polylysine region and methylation of K-Ras are critical for
the interaction between K-Ras and microtubules. J Biol Chem
2000, 275(52):41251-41257.
20. Shi YQ, Rando RR: Kinetic mechanism of isoprenylated protein
methyltransferase. J Biol Chem 1992, 267(14):9547-9551.
21. Stephenson RC, Clarke S: Identification of a C-terminal protein
carboxyl methyltransferase in rat liver membranes utilizing
a synthetic farnesyl cysteine-containing peptide substrate. J
Biol Chem 1990, 265(27):16248-16254.
22. Perez-Sala D, Tan EW, Canada FJ, Rando RR: Methylation and
demethylation reactions of guanine nucleotide-binding pro-
teins of retinal rod outer segments. Proc Natl Acad Sci U S A 1991,
88(8):3043-3046.
23. Dai Q, Choy E, Chiu V, Romano J, Slivka SR, Steitz SA, Michaelis S,
Philips MR: Mammalian prenylcysteine carboxyl methyltrans-
ferase is in the endoplasmic reticulum.  J Biol Chem 1998,
273(24):15030-15034.
24. Zhang L, Sachs CW, Fine RL, Casey PJ: Interaction of prenyl-
cysteine methyl esters with the multidrug resistance
transporter. J Biol Chem 1994, 269(23):15973-15976.
25. Bodansky MaB A: The practice of peptide synthesis. New York:
Springer-Verlag; 1984. 
26. Mark J, Brown PDM, Lever David C, Epstein William W, Dale Poulter
C: Prenylated proteins. A convenient synthesis of farnesyl
cysteinyl thioethers. J Biol Chem 1994, 269:15973-15976.
Proposed kinetic mechanism of human Icmt Figure 6
Proposed kinetic mechanism of human Icmt. See text 
for details.
E
E
AdoMet
BFC
AdoMet
BFCME
AdoHcy
E
AdoMet
BFC
E
AdoHcy
BFCME
E
AdoHcyPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biochemistry 2004, 5:19 http://www.biomedcentral.com/1471-2091/5/19
Page 12 of 12
(page number not for citation purposes)
27. Otto JC, Kim E, Young SG, Casey PJ: Cloning and characteriza-
tion of a mammalian prenyl protein-specific protease. J Biol
Chem 1999, 274(13):8379-8382.
28. Segel IH: Enzyme kinetics. New York: John Wiley & Sons; 1975. 
29. Fersht A: Structure and Mechansim in protein science. New
York: WH Freeman and Company; 1999. 
30. Hurst RO: The analysis of dead-end inhibition patterns for
multisubstrate systems. Can J Biochem 1969, 47(2):91-109.
31. Tan EW, Perez-Sala D, Canada FJ, Rando RR: Identifying the rec-
ognition unit for G protein methylation.  J Biol Chem 1991,
266(17):10719-10722.
32. Carman GM, Deems RA, Dennis EA: Lipid signaling enzymes and
surface dilution kinetics. J Biol Chem 1995, 270(32):18711-18714.
33. Clarke S, Tamanoi F: Fighting cancer by disrupting C-terminal
methylation of signaling proteins.  J Clin Invest 2004,
113(4):513-515.